ArriVent BioPharma, Inc. (AVBP) · Oct 26, 2026 · Other events
Above the bar — 44.8% ORR and 93.1% DCR at 6 mg/kg in CRC
ArriVent’s Phase 1 data show meaningful ARR-217 responses in heavily pretreated colorectal cancer, giving its ADC pipeline a needed lift after FURVENT failed.
ArriVent is a clinical-stage oncology company whose lead firmonertinib program suffered a major setback when the Phase 3 FURVENT trial failed its primary progression-free-survival endpoint on October 6, 2026; ARR-217 is therefore an important early diversification asset rather than just another pipeline update. The company’s broader strategy is shifting toward a portfolio that combines firmonertinib with next-generation antibody-drug conjugates.
The clinical signal clears the early-stage bar. The ESMO readout showed a 44.8% objective response rate in efficacy-evaluable colorectal cancer patients at 6 mg/kg, with a 93.1% disease-control rate; across doses of at least 4 mg/kg, ORR was 34.2%. Those are preliminary, non-randomized Phase 1 results, but they are meaningful in a heavily pretreated population and support moving into dose optimization. The data also showed responses in both RAS wild-type and RAS-mutant disease, broadening the potential addressable group.
| ARR-217 Phase 1 readout | Result |
|---|---|
| Patients treated | 123 across six dose levels, including 113 with colorectal cancer (Filing: study description) |
| CRC ORR at 6 mg/kg | 44.8% (13/29) |
| CRC DCR at 6 mg/kg | 93.1% (27/29) |
| CRC ORR at ≥4 mg/kg | 34.2% (25/73) |
| Treatment-related discontinuation | 1 of 123 patients (0.8%) |
The safety profile is supportive, though not yet definitive. Most reported adverse events were cytopenias and gastrointestinal toxicities, predominantly Grade 1 or 2, with no interstitial lung disease reported and only one treatment-emergent-adverse-event discontinuation. That combination of activity and tolerability is the main reason this looks better than a routine first-in-human signal, although the dataset is still small and follow-up is immature.
This was partly anticipated, but the magnitude is new. ArriVent had already announced that ARR-217 data would be presented at ESMO, so the existence and timing of the update were known. The actual response rates and safety details were the new information. The filing says 123 heavily pretreated GI-cancer patients had been treated across six dose levels, and management expects dose-optimization data in 2027. 〔0〕 〔1〕
The limitation is strategic, not an immediate clinical failure. ARR-217 is still an early Phase 1 asset, and the 8-K itself does not provide a full clinical-results table; the detailed efficacy numbers come from the ESMO presentation. It therefore strengthens the pipeline story but does not replace the lost validation from firmonertinib’s failed FURVENT study or establish registrational efficacy.
Bottom line: ARR-217 produced a genuinely encouraging early signal at a time when ArriVent needed another credible development engine. It materially improves the pipeline narrative, but the value of the program still depends on confirmation in dose optimization and later-stage studies, not this Phase 1 snapshot alone.
Phase 1b dose-optimization data expected in 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!